N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea | 224585-45-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea
• 英文别名: YF792N2Exv；1-(3,5-dichlorophenyl)-3-[[4-(1H-imidazol-5-ylmethyl)phenyl]methyl]urea
• CAS: 224585-45-9
• 化学式: C₁₈H₁₆Cl₂N₄O
• 分子量: 375.257
• InChiKey: CXNCQFJNXQAFND-UHFFFAOYSA-N

物化性质

• 沸点：
  590.1±50.0 °C(Predicted)
• 密度：
  1.406±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  69.8
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea 、 碘甲烷 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-(3,5-Dichloro-phenyl)-3-[4-(3-methyl-3H-imidazol-4-ylmethyl)-benzyl]-urea 、 1-(3,5-Dichloro-phenyl)-3-[4-(1-methyl-1H-imidazol-4-ylmethyl)-benzyl]-urea
  参考文献：
  名称：

  Identification of a novel, orally bioavailable histamine H 3 receptor antagonist based on the 4-benzyl-(1 H -imidazol-4-yl) template

  摘要：

  A novel series of histamine H-3 receptor antagonists, based on the 4-benzyl-(1H-imidazole-4-yl) template, incorporating urea and carbamate linkers has been prepared. Compound 3j is a selective H-3 antagonist and demonstrates excellent oral plasma levels in the rat and monkey. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00055-0
• 作为产物：
  描述：

  4-(1-trityl-1H-imidazol-4-ylmethyl)-benzonitrile 在 镍 吡啶 、 盐酸 、 氨 、 氢气 作用下， 以 甲醇 为溶剂， 生成 N-(3,5-dichlorophenyl)-N'-[[4-[(1H-imidazol-4-yl)methyl]phenyl]methyl]urea
  参考文献：
  名称：

  Identification of a novel, orally bioavailable histamine H 3 receptor antagonist based on the 4-benzyl-(1 H -imidazol-4-yl) template

  摘要：

  A novel series of histamine H-3 receptor antagonists, based on the 4-benzyl-(1H-imidazole-4-yl) template, incorporating urea and carbamate linkers has been prepared. Compound 3j is a selective H-3 antagonist and demonstrates excellent oral plasma levels in the rat and monkey. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00055-0

文献信息

• ENZYME INHIBITORS
  申请人：Thormann Michael

  公开号：US20070244177A1

  公开（公告）日：2007-10-18

  There is dislosed herein compounds of formula (I), wherein: R 1 , R 2 , R 3 , R 4 and R 5 are defined throughout the description and the claims. The compounds of formula (I) are useful for the treatment of neurological diseases and neurodegenerative diseases, e.g. anxiety, depression, Alzheimer's disease etc.

  本文披露了公式（I）的化合物，其中：R1、R2、R3、R4和R5在描述和权利要求中有定义。公式（I）的化合物可用于治疗神经疾病和神经退行性疾病，例如焦虑、抑郁、阿尔茨海默病等。
• COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES
  申请人：SCHERING CORPORATION

  公开号：EP1117405A2

  公开（公告）日：2001-07-25
• NOVEL INHIBITORS OF GLUTAMINYL CYCLASE
  申请人：Probiodrug AG

  公开号：EP1713780B1

  公开（公告）日：2012-01-18
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• US6103735A
  申请人：——

  公开号：US6103735A

  公开（公告）日：2000-08-15